BioMarin Pharmaceutical, Inc. (BMRN)
57.18
-1.26
(-2.16%)
USD |
NASDAQ |
Oct 02, 16:00
57.30
+0.12
(+0.21%)
After-Hours: 20:00
BioMarin Pharmaceutical Price to Book Value : 1.750 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.750 |
| October 01, 2026 | 1.789 |
| September 30, 2026 | 1.837 |
| September 29, 2026 | 1.833 |
| September 28, 2026 | 1.820 |
| September 25, 2026 | 1.845 |
| September 24, 2026 | 1.878 |
| September 23, 2026 | 1.904 |
| September 22, 2026 | 1.94 |
| September 21, 2026 | 1.961 |
| September 18, 2026 | 1.958 |
| September 17, 2026 | 1.992 |
| September 16, 2026 | 1.982 |
| September 15, 2026 | 1.973 |
| September 14, 2026 | 2.033 |
| September 11, 2026 | 2.011 |
| September 10, 2026 | 2.006 |
| September 09, 2026 | 1.972 |
| September 08, 2026 | 1.979 |
| September 04, 2026 | 2.037 |
| September 03, 2026 | 2.034 |
| September 02, 2026 | 2.050 |
| September 01, 2026 | 1.985 |
| August 31, 2026 | 1.997 |
| August 28, 2026 | 1.980 |
| Date | Value |
|---|---|
| August 27, 2026 | 1.999 |
| August 26, 2026 | 2.009 |
| August 25, 2026 | 2.024 |
| August 24, 2026 | 1.992 |
| August 21, 2026 | 2.042 |
| August 20, 2026 | 2.072 |
| August 19, 2026 | 2.122 |
| August 18, 2026 | 2.051 |
| August 17, 2026 | 2.040 |
| August 14, 2026 | 2.062 |
| August 13, 2026 | 2.098 |
| August 12, 2026 | 2.150 |
| August 11, 2026 | 2.129 |
| August 10, 2026 | 2.109 |
| August 07, 2026 | 1.954 |
| August 06, 2026 | 1.882 |
| August 05, 2026 | 1.834 |
| August 04, 2026 | 1.859 |
| August 03, 2026 | 1.837 |
| July 31, 2026 | 1.838 |
| July 30, 2026 | 1.855 |
| July 29, 2026 | 1.879 |
| July 28, 2026 | 1.900 |
| July 27, 2026 | 1.845 |
| July 24, 2026 | 1.816 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 21.70 |
| Vertex Pharmaceuticals, Inc. | 6.315 |
| Ascendis Pharma A/S | 9.112 |
| BridgeBio Pharma, Inc. | -- |
| Incyte Corp. | 3.652 |
Price to Book Value Related Metrics
| PE Ratio | 154.17 |
| PS Ratio | 3.211 |
| Price to Free Cash Flow | 15.31 |
| Price | 57.18 |
| Earnings Yield | 0.65% |
| Market Cap | 11.07B |
| Operating PE Ratio | 17.35 |
| Normalized PE Ratio | 29.03 |